<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934
Filed by the registrant (X)
Filed by a party other than the registrant ( )
Check the appropriate box:
( ) Preliminary proxy statement
( ) Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)
(2))
(X) Definitive proxy statement
( ) Definitive additional materials
( ) Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12
GELMAN SCIENCES INC.
(Name of registrant as specified in its charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of filing fee (Check the appropriate box):
(X) $125 per Exchange Act Rules-0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2),
or Item 22(a)(2) of Schedule 14A
( ) $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3)
( ) Fee computed on table below per Exchange Act Rules
14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
_____________________
(2) Aggregate number of securities to which transaction applies:
_____________________
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:____________________________________________
(4) Proposed maximum aggregate value of transaction:
____________________________
(5) Total fee paid: $____________________________
( ) Fee paid previously with preliminary materials
( ) Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount previously paid:
________________________________________________
(2) Form, Schedule or Registration Statement no.: ___________________
(3) Filing party:____________________________________________________
(4) Date filed: _____________________________________________________
<PAGE> 2
GELMAN SCIENCES INC.
600 SOUTH WAGNER ROAD
ANN ARBOR, MICHIGAN 48103
November 15, 1995
To our Shareholders:
You are cordially invited to attend the Annual Meeting of Shareholders to
be held on Friday, December 15, 1995, at 11:00 a.m. at the Board of Governors
Room, American Stock Exchange, 86 Trinity Place, New York, New York 10006.
This year we will elect three directors whose term will expire at the 1998
Annual Meeting. The shareholders will also be asked to ratify and approve the
issuance of warrants to non-employee directors since September 1, 1992. The
shareholders will consider and vote on a proposed Non-Employee Director Stock
Plan. Further, the shareholders will be requested to approve and ratify the
adoption of an Executive Stock Ownership Plan. Enclosed with this letter is (1)
a Notice of Annual Meeting, (2) a Proxy Statement which contains information
with respect to the nominees, as well as the other directors who will continue
in office, and (3) the Company's 1995 Annual Report.
It is important that your shares be voted, and we hope that you will be
able to attend the Annual Meeting. We urge you to execute and return the
enclosed form of proxy as soon as possible, whether or not you expect to attend
the Annual Meeting in person.
Sincerely,
Charles Gelman
Chairman
<PAGE> 3
GELMAN SCIENCES INC.
600 SOUTH WAGNER ROAD
ANN ARBOR, MICHIGAN 48103
------------------------------
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
DECEMBER 15, 1995
The Annual Meeting of Shareholders of Gelman Sciences Inc., a Michigan
corporation (the "Company"), will be held at the Board of Governors Room,
American Stock Exchange, 86 Trinity Place, New York, New York 10006, on December
15, 1995, at 11:00 a.m., local time, for the following purposes:
1. To elect three directors to serve until the 1998 Annual Meeting of
Shareholders and until a successor is elected and qualified.
2. To ratify and approve the issuance of warrants to non-employee
directors since September 1, 1992.
3. To ratify and approve a proposed Non-Employee Director Stock Plan.
4. To ratify and approve the adoption of an Executive Stock Ownership
Plan.
5. To transact such other business as may properly come before the
meeting and any adjournment thereof.
The Board of Directors has fixed the close of business on November 6, 1995,
as the record date for the determination of shareholders entitled to notice of
and to vote at the Annual Meeting.
All shareholders are cordially invited to attend the meeting in person.
However, whether or not you plan to attend, please fill in, date, sign and
return the enclosed proxy card in the envelope provided. If you attend the
meeting, you may withdraw your proxy and vote your own shares.
A copy of the Annual Report of the Company for the fiscal year ended July
31, 1995, accompanies this notice.
By Order of the Board of Directors
Edward J. Levitt
Secretary
Ann Arbor, Michigan
November 15, 1995
ALL SHAREHOLDERS ARE REQUESTED TO SIGN, DATE
AND RETURN THE ACCOMPANYING PROXY IN
THE ENCLOSED ENVELOPE
<PAGE> 4
GELMAN SCIENCES INC.
600 SOUTH WAGNER ROAD
ANN ARBOR, MICHIGAN 48103
-------------------------------
PROXY STATEMENT
-------------------------------
ANNUAL MEETING OF SHAREHOLDERS
DECEMBER 15, 1995
This Proxy Statement is furnished in connection with the solicitation by
the Board of Directors of the Company of the accompanying proxy to be voted at
the Annual Meeting of Shareholders to be held on Friday, December 15, 1995, at
11:00 a.m. local time and at any adjournment thereof. Shares represented by duly
executed proxies in the accompanying form received by the Board of Directors
prior to the meeting will be voted at the meeting. A shareholder who signs and
returns a proxy in the accompanying form may revoke it prior to or at the
meeting by giving notice to the Secretary.
The close of business on November 6, 1995, has been fixed as the record
date for the determination of shareholders entitled to notice of and to vote at
the meeting ("Record Date"). On that date the Company had outstanding 7,827,515
shares of common stock, par value $.10 per share ("Common Stock"), each of which
is entitled to one vote. For information concerning principal shareholders, see
the section captioned "Principal Shareholders," below.
The mailing address of the principal executive offices of the Company is
600 South Wagner Road, Ann Arbor, Michigan 48103-9019. This Proxy Statement,
together with the related Proxy Card and the Company's 1995 Annual Report to
Shareholders, is being mailed to the shareholders of the Company on or about
November 15, 1995.
ELECTION OF DIRECTORS
Three directors are to be elected at the 1995 Annual Meeting. The Board of
Directors proposes that Kim A. Davis, Dr. Saul H. Hymans and Dr. Nina I.
McClelland, each of whose term as director is expiring be re-elected. These
nominees would serve until the 1998 Annual Meeting and until their successors
are elected and qualified. Set forth below for the nominees for director and for
each director whose term will continue after the 1995 Annual Meeting is a brief
statement, including age, principal occupation and business experience during
the past five years. The number of shares of the Company Common Stock
beneficially owned by each such person is shown under the caption "Security
Ownership of Management," below. Proxies on which no choice is marked will be
voted in favor of the election of each nominee. If any nominee should be unable
or unwilling to serve, it is intended that proxy votes will be cast for a
substitute nominee designated by the Board of Directors, unless authority to
vote for the election of directors is specifically withheld. Under Michigan law
and the Company's charter documents, if a quorum is present at the meeting, the
three persons who receive the greatest number of votes cast for the election of
directors at the meeting by the shares present in person or by proxy and
entitled to vote will be elected as directors. The Board of Directors has no
reason to believe that Mr. Davis, Dr. Hymans or Dr. McClelland will be unable or
unwilling to serve if elected.
<PAGE> 5
DIRECTORS AND NOMINEES FOR DIRECTOR
(TERM EXPIRING IN 1995)
<TABLE>
<CAPTION>
PRINCIPAL OCCUPATION
FOR PAST FIVE YEARS
NAME AGE AND OTHER INFORMATION
- ------------------------- --- --------------------------------------------------------
<S> <C> <C>
Kim A. Davis............. 44 Since May 1993, President and Chief Operating Officer of
the Company; from January 1991 to May 1993, Chief
Operating Officer of Promega Corporation
(biotechnology); Director of the Company since March
1995
Saul H. Hymans........... 58 Professor of Economics and Statistics, and Director,
Research Seminar in Quantitative Economics, The
University of Michigan; Director of the Company since
1980
Nina I. McClelland....... 66 Since May 1995, President of Nina I. McClelland, LLC
(consulting services); from January 1995 to May 1995,
Chairman, National Sanitation Foundation International,
Ann Arbor, Michigan; until January 1995, Chairman of the
Board of Directors, President, Chief Executive Officer
and Treasurer of National Sanitation Foundation, Ann
Arbor, Michigan; Adjunct Professor, School of Public
Health, The University of Michigan; Director of the
Company since 1989
</TABLE>
(TERM EXPIRING IN 1997)
<TABLE>
<CAPTION>
PRINCIPAL OCCUPATION
FOR PAST FIVE YEARS
NAME AGE AND OTHER INFORMATION
- ------------------------- --- --------------------------------------------------------
<S> <C> <C>
Robert M. Collins........ 64 Since April 1991, an Independent Consultant (business
strategy); from 1990 to April 1991, President, Cobe
Laboratories Inc.; from 1989, Chief Executive Officer of
Cobe Laboratories Inc.; Director of the Company since
1994
Charles Gelman........... 63 Chairman of the Board of Directors and Chief Executive
Officer of the Company; President of the Company until
April 1988 and from October 1990 to May 1993; Director
of the Company since 1959
Charles Newman........... 54 President of ReCellular Inc. (remanufacturer of cellular
phones) since 1989; Director of the Company since 1992
</TABLE>
(TERM EXPIRING IN 1996)
<TABLE>
<CAPTION>
PRINCIPAL OCCUPATION
FOR PAST FIVE YEARS
NAME AGE AND OTHER INFORMATION
- ------------------------- --- --------------------------------------------------------
<S> <C> <C>
John A. Geishecker,
Jr..................... 58 Vice President, Corporate Finance, Rule Industries, Inc.
(diversified manufacturer), Gloucester, Massachusetts;
Director of the Company since 1978
Hajime Kimura............ 45 President and Chief Executive Officer of JMS Co., Ltd.
(medical supplier) since October 1991; from August 1991
to October 1991, Managing Director, International
Operations of JMS Co., Ltd.; from August 1989 to August
1991, Director, Head of Tokyo office of JMS Co., Ltd.;
Director of the Company since 1994
</TABLE>
- ---------------
John A. Geishecker, Jr., is a director of Rule Industries, Inc.; Dr.
McClelland serves as a director of First of America Bank -- Ann Arbor.
2
<PAGE> 6
There are and during the past five years there have been no legal
proceedings material to an evaluation of the ability of any director or
executive officer of the Company to act in such capacity or of his or her
integrity.
COMMITTEES
The Company has a standing Executive Committee which consists of Charles
Gelman and John A. Geishecker, Jr. During the fiscal year ended July 31, 1995,
the Executive Committee held three meetings. The Executive Committee meets on
call and has authority to act on most matters during the intervals between
meetings of the Board of Directors.
The Audit Committee of the Board of Directors, which consists of John A.
Geishecker, Jr., Saul H. Hymans and Charles Newman, met one time during the
fiscal year ended July 31, 1995. The functions performed by the Audit Committee
are: (1) nominating the Company's independent auditors for approval by the Board
of Directors, (2) reviewing with the independent auditors the scope, cost and
results of the auditing engagement, (3) reviewing and approving fees for audit
and nonaudit professional services provided by the independent auditors, (4)
reviewing the reports submitted by the independent auditors and (5) reviewing
the adequacy of the Company's system of internal accounting controls.
The Board of Directors has no nominating committee or committee performing
similar functions. The functions normally performed by such a committee are the
responsibility of the entire Board of Directors.
The Company has a Compensation Committee which consists of Robert M.
Collins, John A. Geishecker, Jr., and Nina I. McClelland. The Compensation
Committee met three times during the fiscal year ended July 31, 1995. The
Compensation Committee recommends to the Board of Directors compensation
arrangements for senior management and directors, recommends to the Board
compensation plans in which officers or directors are eligible to participate,
and grants options under the 1988 Stock Plan.
The Board of Directors met four times during the fiscal year ended July 31,
1995. Dr. Hajime Kimura attended less than 75% of the meetings of the Board of
Directors.
COMPENSATION OF DIRECTORS
During the fiscal year ended July 31, 1995, each director of the Company,
other than Charles Gelman and Kim A. Davis, received a retainer of $4,000 and
was paid $2,000 per board meeting attended. Directors Saul H. Hymans, Nina I.
McClelland and Charles Newman were also each paid $1,200 for committee work. Mr.
Gelman and Mr. Davis, as employees of the Company, were not compensated
separately for attendance at board or committee meetings. During the fiscal
year, no other non-employee directors received compensation for committee work.
At the September 20, 1995, Board of Directors meeting, the compensation of
each non-employee director was increased to $2,000 per day for each day on which
such a director attends a meeting of the Board of Directors starting September
20, 1995. At that same meeting, the Board of Directors voted to compensate
non-employee directors, effective September 20, 1995, who are members of the
Audit Committee or the Compensation Committee in the amount of $1,000 per
meeting attended on a day separate from a day on which a meeting of the Board of
Directors is held.
Dr. Hajime Kimura was granted a stock warrant for 9,000 shares at the
closing price on the American Stock Exchange on September 1, 1994, of $14.25 per
share, for his appointment to the Board, effective September 2, 1994.
At the September 20, 1995, Board of Directors meeting, the Board of
Directors adopted a Non-Employee Director Stock Plan, subject to shareholder
approval at the forthcoming Annual Meeting of Shareholders, under which a newly
elected non-employee director is to receive upon initial election to office an
option to purchase 9,000 shares and on each July 31 following reelection to
office an option to purchase 1,000 shares, the price of the shares being the
closing price per share of Common Stock on the American Stock Exchange on the
last trading day immediately preceding the date of grant. A more detailed
discussion of this plan is set forth under the caption "PROPOSAL TO APPROVE
NON-EMPLOYEE DIRECTOR STOCK PLAN," below.
3
<PAGE> 7
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
executive officers and directors, and persons who beneficially own more than ten
percent of the Company's Common Stock, to file initial reports of ownership and
reports of changes in ownership with the Securities and Exchange Commission and
the American Stock Exchange and to furnish copies of all such Section 16(a)
reports to the Company.
Based solely on a review of the copies of such forms furnished to the
Company and written representations from the Company's executive officers and
directors, the Company believes that during the last fiscal year all Section
16(a) filing requirements applicable to its executive officers, directors and
greater than ten percent beneficial owners were complied with.
PROPOSAL TO APPROVE WARRANTS ISSUED TO
NON-EMPLOYEE DIRECTORS SINCE SEPTEMBER 1, 1992
The Board of Directors recommends the ratification and approval of the
issuance of warrants for a total of 40,500 shares of the Common Stock of the
Company to non-employee directors since September 1, 1992. Each warrant is
subject to an agreement prohibiting exercise within six months following the
date of grant. The per share exercise price of each warrant is the closing price
per share of the Common Stock of the Company on the American Stock Exchange on
the last trading day immediately preceding the date of grant. The names of the
directors who were granted any such warrant, the date of grant, the number of
shares subject to each warrant and the exercise price are as set forth below
(number of shares and exercise price have been adjusted to take into account any
stock splits that occurred subsequent to date of grant). Warrants issued to
non-employee directors previous to September 1, 1992, were approved periodically
by the shareholders of the Company.
<TABLE>
<CAPTION>
NAME GRANT DATE SHARES EXERCISE PRICE($)
------------------------------ ----------------- ------ -----------------
<S> <C> <C> <C>
Robert M. Collins June 17, 1994 9,000 10.920
John A. Geishecker, Jr. June 17, 1994 4,500 10.920
Saul H. Hymans June 17, 1994 4,500 10.920
Hajime Kimura September 2, 1994 9,000 14.250
Nina I. McClelland June 17, 1994 4,500 10.920
Charles Newman September 2, 1992 4,500 3.333
June 17, 1994 4,500 10.920
------
Total 40,500
======
</TABLE>
On October 31, 1995, the closing price per share of the Common Stock of the
Company on the American Stock Exchange was $21.375.
Under current federal income tax law, a director who was granted a warrant
will not realize taxable income by reason of such grant. However, upon the
exercise of a warrant, the excess of the fair market value over the exercise
price of the shares purchased will be treated as compensation and will be taxed
to the director at ordinary income rates. The Company will be entitled to a tax
deduction in the amount of any compensation income realized by the director.
The purpose of the issuance of these warrants was to align the interests of
non-employee directors with the interests of shareholders of the Company, with
the goal of maximizing return on shareholder investment.
Unless instructed to abstain or to vote against the proposal, or authority
to vote is withheld, the persons named in the accompanying proxy will vote the
shares represented thereby in favor of the approval and ratification of the
issuance. The issuance will be approved and ratified if a majority of the
outstanding shares entitled to be voted at the meeting are voted in favor of the
proposal. Under Michigan law and the Company's charter documents, if a quorum is
present at the meeting, the proposal must be approved by a majority of the votes
present in person or represented by proxy at the meeting. The withholding of a
vote with respect to any share will have the practical effect of a vote against
the proposal; a broker non-vote with respect to any share will not affect the
passage of the proposal, since the share is not considered present for voting
purposes.
4
<PAGE> 8
The Board of Directors, including the employee directors, recommends a vote
FOR ratification and approval of all warrants.
PROPOSAL TO APPROVE NON-EMPLOYEE DIRECTOR STOCK PLAN
On September 20, 1995, the Board of Directors adopted a Non-Employee
Director Stock Plan (the "Director Plan"), subject to approval and ratification
by the Company's shareholders. The following summary describes the principal
provisions of the Director Plan. A copy of this plan will be furnished without
charge to any shareholder upon written request to the Company.
PURPOSE
The purpose of the Director Plan is to provide non-employee directors of
the Company an opportunity to participate in future appreciation in the share
value of the Company's Common Stock, with the goal of maximizing return on
shareholder investment. The opportunity to participate in stock appreciation is
intended to enable the Company to attract and retain superior Board Members.
Currently the Company has six directors eligible to participate in the Director
Plan.
ADMINISTRATION
The Director Plan will be administered by a committee (the "Committee")
comprised of three or more directors or executive officers of the Company, each
of whom may be (but need not be) an employee or employee-director of the
Company, none of whom are eligible to participate in the plan. Only non-employee
directors of the Company ("Participants") are eligible to participate in the
plan.
The Director Plan provides for the grant of options to purchase 9,000
shares of Common Stock upon each Participant's initial election as a director
and an option to purchase an additional 1,000 shares of Common Stock on July 31
of each year following re-election to office. Each director may also elect to
receive Common Stock in an amount equal to, and in lieu of, all or part of the
fees that otherwise would be paid by the Company to such director as
compensation for serving on the Board. For the purposes of such payment in
Common Stock, a share of Common Stock will be valued at the closing price on the
American Stock Exchange on the last trading day of the fiscal quarter prior to
the scheduled date for payment of such fees.
TERMS OF OPTIONS
Options may not be exercised during the first six months after grant, but
may be exercised in whole or in part from time to time thereafter provided the
Participant's status as a non-employee director of the Company has not changed
and the Director Plan remains in effect. Options granted under the Director Plan
which remain unexercised expire ten years after the date of the grant.
The exercise price for options granted under the Director Plan shall be the
closing price per share of the Common Stock on the American Stock Exchange on
the last trading day immediately preceding the date of grant. The exercise price
may be payable, at the election of the Participant, in cash or in shares of
Common Stock valued at the closing price for the Common Stock on the American
Stock Exchange on the last trading date immediately preceding the date of
exercise.
On October 31, 1995, the closing price of the Common Stock of the Company
on the American Stock Exchange was $21.375.
The Company will assist any Participant in effecting the exercise of an
option by delivering to the Participant, in lieu of a certificate evidencing
such shares, the amount by which the sale price of such shares exceeds the
exercise price, after deducting applicable taxes and brokerage fees. Each
Participant will receive an automatic grant of an additional option with an
exercise price equal to the current market value of such shares for an equal
amount of shares (subject to the plan limit) upon the exercise of an option
through delivery of shares of Common Stock.
The exercise price and the number of shares covered by each option will be
adjusted by the Committee to prevent the dilution or enlargement of the rights
of any Participant that would otherwise result from any stock
5
<PAGE> 9
dividend, stock split, combination of shares, recapitalization or other change
in the capital structure of the Company, or any merger, consolidation,
reorganization or liquidation of the Company.
TRANSFERABILITY
An option granted pursuant to the Director Plan is not transferable other
than by will or the laws of descent and distribution. An option is exercisable
during a Participant's lifetime only by the Participant, except that in the case
of incompetence or disability of a Participant an option may be exercised on
behalf of the Participant by his or her guardian or legal representative. In the
event of the death of any Participant any option issued to that Participant
which is exercisable on the date of death may be exercised for a period equal to
the lesser of 180 days following the date of death or the expiration date of the
option. In the event the Participant's service on the Board is terminated for
any other reason, any option exercisable on the date of termination may be
exercised by the Participant for a period equal to the lesser of 90 days
following the date of termination or the expiration date of the option.
NUMBER OF SHARES SUBJECT TO THE PLAN
The maximum number of shares of Common Stock with respect to which options
may be granted under the Director Plan in any fiscal year of the Company is
41,000, subject to adjustment as a result of reorganization, recapitalization,
stock splits, stock dividends or similar corporate transactions. There is no
limit on the number of shares issuable in lieu of directors' fees. The shares
underlying the options and those issuable in lieu of directors' fees may be
either authorized and unissued shares or shares which have been reacquired by
the Company.
AMENDMENTS; TERMINATION
The Committee may amend the Director Plan from time to time and terminate
the Plan; however, the Committee may not increase the maximum number of shares
of Common Stock that may be issued under the plan, change the designation of
eligible Participants, or cause Rule 16b-3 to cease to be applicable to the plan
without approval of the shareholders of the Company. Moreover, neither the plan
nor any stock option agreement issued thereunder may be amended more than once
every six months other than to comport with changes in the Internal Revenue Code
or ERISA.
TAX EFFECTS
Under current federal income tax law, a director who is granted an option
will not realize taxable income by reason of such grant. However, upon the
exercise of an option, the excess of the fair market value over the option price
of the shares of Common Stock purchased will be treated as compensation and will
be taxed to the director at ordinary income rates. The Company will be entitled
to a tax deduction in the amount of any compensation income realized by the
optionee.
Common Stock received by directors in lieu of fees will generally be
taxable as ordinary income to the director at the time of receipt.
REQUISITE VOTE
Unless instructed to abstain or to vote against the proposal, or authority
to vote is withheld, the persons named in the accompanying proxy will vote the
shares represented thereby in favor of the proposed Director Plan. The Director
Plan will be adopted if a majority of the outstanding shares entitled to be
voted at the meeting are voted in favor of such plan. Under Michigan law and the
Company's charter documents, if a quorum is present at the meeting, the proposal
must be approved by a majority of the votes present in person or represented by
proxy at the meeting. The withholding of a vote with respect to any share will
have the practical effect of a vote against the proposal; a broker non-vote with
respect to any share will not affect the passage of the proposal, since the
share is not considered present for voting purposes.
On October 31, 1995, the closing price of the Common Stock of the Company
on the American Stock Exchange was $21.375.
6
<PAGE> 10
The Board of Directors, including the employee directors, recommends a vote
FOR ratification and approval of the Director Plan.
PROPOSAL TO APPROVE EXECUTIVE STOCK OWNERSHIP PLAN
On September 20, 1995, the Board of Directors adopted an Executive Stock
Ownership Plan ("Executive Plan"), subject to shareholder approval and
ratification. The Executive Plan is a feature of the Company's Executive
Compensation Plan, also adopted by the Board on September 20, 1995. The
following summary describes the principal provisions of the Executive Plan. A
copy of the Executive Plan will be furnished without charge to any shareholder
upon written request to the Company.
PURPOSE
The purpose of the Executive Plan is to foster and promote the long-term
growth and performance of the Company by requiring and enabling the acquisition
of a significant personal equity interest in the Company by those Company
executives upon whose judgment and efforts the Company is largely dependent for
the successful conduct of its business. As equity holders, the Company
executives will participate in future appreciation in the share value of the
Company's stock, thus further aligning their interests with the interests of
other shareholders of the Company, with the goal of maximizing return on
shareholder investment. The opportunity to participate in Company stock
appreciation should enable the Company to attract and retain key executives
critical to the long-term success of the Company.
ADMINISTRATION
The Executive Plan will be administered by a committee (the "Committee") of
three or more members of the Board, none of whom will be an employee of the
Company or eligible to participate in the plan. All decisions made by the
Committee pursuant to the provisions of the plan and related orders or
resolutions of the Board shall be final and conclusive.
The Board or its compensation committee will make an annual determination
as to the dollar amount of a bonus pool and the allocation of such pool among
the Company's executive officers and other employees. Pursuant to the Executive
Plan, it is the goal of the Company that each executive officer acquire and
retain ownership of no fewer than that number of shares of the Company's Common
Stock with a value equal to fifty percent (50%) of such executive's annual base
salary, as adjusted from time to time. Consistent with that goal, if an
executive owns shares in an amount equal in value to less than fifty percent
(50%) of such executive's base salary, the annual bonus to that executive will
be paid in the form of a specified amount of Common Stock, and the remainder of
the bonus will be paid in cash. The number of shares of Common Stock paid to the
executive will be sufficient to bring the value of the executive's Common Stock
ownership up to fifty percent (50%) of the executive's base annual salary for
that fiscal year, subject to the limitation that the value of the Common Stock
component of the bonus paid to an executive with respect to any year will not
exceed the lesser of thirty percent (30%) of that executive's annual bonus or
ten percent (10%) of that executive's annual base salary for that year. The
value of the shares an executive owns and the number of shares, if any, paid to
that executive as part of the annual bonus is based upon the closing price per
share of the Common Stock on the principal stock exchange on which the Common
Stock is traded on July 31 (or the last trading day prior thereto if July 31 is
not a trading day) of the fiscal year for which the bonus is awarded.
PARTICIPANTS
The Company's chief executive officer, its chief operating officer, and all
other executive officers of the Company are eligible to participate in the
Executive Plan.
STOCK SUBJECT TO EXECUTIVE PLAN
The aggregate number of shares of Common Stock which may be issued under
the Executive Plan shall not exceed 100,000 shares. Such number of shares will
be adjusted as a result of reorganization, capitalization,
7
<PAGE> 11
stock split, stock dividend, or similar corporate transaction. Such shares may
be either authorized and unissued shares or shares which have been reacquired by
the Company.
AMENDMENTS
The Executive Plan may be terminated or suspended or amended from time to
time by the Committee or the Board, with the provision that no amendment shall
(i) increase the maximum number of shares of Common Stock that may be issued
under the plan (subject to the adjustments described above), (ii) change the
designation of plan Participants, or (iii) cause Rule 16b-3 (or any successor
rule) to cease to be applicable to the plan without further approval of the
shareholders of the Company. The Executive Plan may also not be amended more
than once every six months other than to comport with changes in the Internal
Revenue Code or ERISA.
TERM OF PLAN
The Executive Plan will remain in effect until all the Common Stock subject
to it shall have been awarded pursuant to the provisions thereof, unless sooner
terminated by the Board or the Committee.
REQUISITE VOTE
Unless instructed to abstain or to vote against the proposal, or authority
to vote is withheld, the persons named in the accompanying proxy will vote the
shares represented thereby in favor of the proposed Executive Plan. The
Executive Plan will be adopted if a majority of the outstanding shares entitled
to be voted at the meeting are voted in favor of such plan. Under Michigan law
and the Company's charter documents, if a quorum is present at the meeting, the
proposal must be approved by a majority of the votes present in person or
represented by proxy at the meeting. The withholding of a vote with respect to
any share will have the practical effect of a vote against the proposal; a
broker non-vote with respect to any share will not affect the passage of the
proposal, since the share is not considered present for voting purposes.
The Board of Directors recommends a vote FOR ratification and approval of the
Executive Plan.
8
<PAGE> 12
COMPENSATION OF EXECUTIVE OFFICERS
SUMMARY COMPENSATION TABLE
The following table sets forth information concerning the compensation for
services in all capacities for the fiscal years ended July 31, 1995 ("Fiscal
1995"); July 31, 1994 ("Fiscal 1994"); and July 31, 1993 ("Fiscal 1993") of
those persons who were, at July 31, 1995, the chief executive officer and the
other four most highly compensated executive officers of the Company (the "Five
Named Officers") and James J. Fahrner, who resigned from the Company in June
1995.
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
-------------------------------------- AWARDS/SECURITIES
NAME AND FISCAL UNDERLYING ALL OTHER
PRINCIPAL POSITION YEAR SALARY($) BONUS($)(1) OPTIONS(#) COMPENSATIONS($)(3)
- ----------------------- ------ --------- ----------- ----------------- -------------------
<S> <C> <C> <C> <C> <C>
Charles Gelman 1995 350,012 150,000 50,000 157,179
Chairman of the 1994 328,000 120,000 56,250 46,637
Board & CEO 1993 328,000 75,000 -- 14,624
Kim A. Davis 1995 233,870 150,000 50,000 11,551
COO & President 1994 186,000 120,000 56,250 2,419
1993 186,000 60,000 56,250 200
James C. Marshall 1995 152,200 14,000 -- 15,250
Sr. Vice President 1994 152,200 30,000 -- 62,239
1993 152,200 30,000 -- 60,481
Robert L. Buker 1995 123,846 14,000 -- 6,018
Vice President, 1994 140,000 15,000 -- 9,348
Corp. Comm. 1993 116,645 15,000 -- 6,434
James J. Fahrner(2) 1995 122,961 0 10,000 4,094
CFO, V.P. 1994 139,000 20,000 -- 9,595
Finance & Treasurer 1993 139,000 20,000 -- 7,345
Mark Sutter 1995 106,923 31,760 5,000 6,751
V.P. R&D 1994 100,000 30,000 -- 7,869
1993 84,962 25,000 18,000 5,156
</TABLE>
- ---------------
(1) Bonuses are shown in the fiscal year earned, but payment is deferred until
the subsequent fiscal year. Mr. Davis' bonus for Fiscal 1993 was paid at the
commencement of his employment.
(2) Mr. Fahrner resigned as Chief Financial Officer, V.P. Finance and Treasurer
on June 16, 1995.
(3) "All Other Compensation" includes the following payments by the Company
during the fiscal year ended July 31, 1995:
(a) Employee Stock Ownership Plan: Mr. Gelman, $1,094; Mr. Davis, $1,094;
Mr. Marshall, $1,094; Mr. Buker, $983; and Mr. Sutter, $1,094. Mr. Fahrner
did not receive any payments under the plan for the fiscal year ended July
31, 1995.
(b) Deferred Compensation Thrift Plan (401(k)): Mr. Gelman, $6,497; Mr.
Davis, $9,155; Mr. Marshall, $6,629; Mr. Buker, $3,773; Mr. Fahrner, $3,323;
and Mr. Sutter, $5,033.
(c) Group Term Life Insurance: Mr. Gelman, $9,126; Mr. Davis, $840; Mr.
Marshall, $1,465; Mr. Buker, $800; Mr. Fahrner, $465; and Mr. Sutter, $162.
(d) In Fiscal 1995, Profit Sharing: Mr. Gelman, Mr. Davis, Mr. Marshall, Mr.
Buker and Mr. Sutter each were paid $462. Mr. Fahrner was paid $306.
(e) Mr. Gelman's other compensation includes $140,000 accrued for 10 year
certain retirement benefit under his employment contract. Mr. Gelman entered
into a new employment contract effective August 1, 1995. Under the terms of
the new contract, the 10-year certain retirement benefit is no longer
provided and the Company is no longer required to maintain the accrual.
(f) Mr. Marshall's other compensation includes $5,600 for accrual of his
termination payment under his employment contract.
9
<PAGE> 13
The following table sets forth additional information concerning stock
option grants made during Fiscal 1995 to the Five Named Officers and Mr.
Fahrner. These grants are also reflected in the Summary Compensation Table. In
addition, in accordance with SEC disclosure rules, the hypothetical gain or
"option spread" for each option grant is shown based on compound annual rate of
stock price appreciation of 5% and 10% from the date of grant to the expiration
date. The assumed rates of growth are prescribed by the SEC and are for
illustration purposes only; they are not intended to predict future stock
prices. The Company has not granted any stock appreciation rights.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE
VALUE AT ASSUMED
ANNUAL RATES OF
STOCK PRICE
APPRECIATION FOR
INDIVIDUAL GRANTS OPTION TERM
- ------------------------------------------------------------------------------------ ------------------------
% OF TOTAL OPTIONS EXERCISE OR
OPTIONS GRANTED TO EMPLOYEES BASE PRICE EXPIRATION
NAME GRANTED(1) IN FISCAL YEAR ($/SH.) DATE 5% ($) 10% ($)
- -------------------- ---------- -------------------- ----------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Charles Gelman 50,000 26.5% 18.875 6/5/2005 1,537,500 2,447,844
Kim A. Davis 50,000 26.5% 18.875 6/5/2005 1,537,500 2,447,844
James C. Marshall 0 -- -- -- -- --
Robert L. Buker 0 -- -- -- -- --
James J. Fahrner(2) 10,000 5.3% 14.875 12/15/2004 93,550 237,050
Mark Sutter 5,000 2.6% 14.875 12/15/2004 46,775 118,535
</TABLE>
- ---------------
(1) The 1988 Plan generally provides for granting of incentive stock options,
non-qualified stock options and stock appreciation rights. The Company has
not granted any stock appreciation rights. The 1988 Plan is administered by
a committee of the Board of Directors. Subject to the limitations imposed
by the 1988 Plan, the committee selects participants, determines the size
of the grant, the option exercise price and the period of vesting. Pursuant
to the 1988 Plan, the exercise price of an incentive stock option must be
no less than the market price of a share of the Company's Common Stock on
the date of the grant. The options granted to Mr. Gelman, Mr. Davis, Mr.
Fahrner, and Mr. Sutter become exercisable one-fourth each year on and
after the anniversary of the grant date. The exercise price must be paid in
cash or, with the consent of the Board of Directors, in whole or in part in
the Company's Common Stock or other property.
(2) Mr. Fahrner resigned on June 16, 1995. Under the terms of his Stock Option
Agreement, to the extent exercisable at termination of employment,
unexercised stock options are exercisable for a 90-day period. The stock
option for 10,000 shares granted during Fiscal 1995 was not exercisable by
Mr. Fahrner on the termination date, and expired. The options therefore
have no present or future realizable value.
10
<PAGE> 14
The following table provides information concerning all exercises of stock
options during Fiscal 1995 by the Five Named Officers and Mr. Fahrner and the
fiscal year-end value of unexercised options on an aggregate basis.
AGGREGATE OPTION EXERCISE IN FISCAL 1995 AND FISCAL YEAR END OPTION VALUE TABLE.
<TABLE>
<CAPTION>
NUMBER OF
SECURITIES VALUE OF
UNDERLYING UNEXERCISED
UNEXERCISED IN-THE-MONEY
OPTIONS OPTIONS
FY-END 1995 FY-END 1995
SHARES ACQUIRED EXERCISABLE/ EXERCISABLE/
NAME ON EXERCISE VALUE REALIZED($)(1) UNEXERCISABLE UNEXERCISABLE($)(2)
- ------------------------- --------------- -------------------- ------------- -------------------
<S> <C> <C> <C> <C>
Charles Gelman 37,500 312,375 0/68,750 0/217,906
Kim A. Davis 0 0 75,000/87,500 833,138/522,819
James C. Marshall 0 0 86,399/ 0 1,367,005/ 0
Robert L. Buker 10,000 113,450 14,750/ 0 231,848/ 0
James J. Fahrner 20,625 283,935 0/ 0 0/ 0
Mark Sutter 2,000 27,606 6,436/15,125 102,317/184,437
</TABLE>
- ---------------
(1) Aggregate market value of the shares of Common Stock covered by the options
on date of exercise less the exercise price of such options.
(2) Options are "in-the-money" if, on July 31, 1995, the market price of the
Common Stock ($19.875) exceeded the exercise price of such option.
TERMINATION OF EMPLOYMENT AND CHANGE OF CONTROL ARRANGEMENTS
Charles Gelman. Pursuant to an employment agreement, Charles Gelman is
employed as Chairman and Chief Executive Officer of the Company for a three-year
term at an annual minimum salary of $350,000 plus bonus, as determined by the
Board of Directors. The agreement provides for the use of an automobile by Mr.
Gelman at no cost to him, and that Mr. Gelman has the right to participate in
medical, disability, retirement and other benefit programs on the same terms and
conditions as other executive employees of the Company. The active employment
period under the agreement commenced August 1, 1995, and is automatically
extended each year on August 1 for one additional year unless notice of
termination is given. Employment terminates upon Mr. Gelman's death or
disability. It also may be terminated by the Company with or without cause
and/or by Mr. Gelman. Should there have been no change in control of the
Company, upon termination by the Company without cause of Mr. Gelman's
employment, Mr. Gelman is to receive termination compensation equal to his
annual salary plus bonus in the year of termination, if the Company is then
achieving or exceeding its projected performance plan, or an amount equal to his
annual salary only, if the Company is not then achieving its projected
performance plan, payable annually for the greater of the remaining balance of
the agreement or two years. If there has been a change in control and Mr. Gelman
resigns within one year of such a change or his employment is terminated by the
Company without cause, Mr. Gelman is to receive termination compensation equal
to his annual salary plus bonus in the year of termination, if the Company is
then achieving or exceeding its projected performance plan, or an amount equal
to his annual salary only, if the Company is not then achieving its projected
performance plan, payable annually for the remaining balance of the agreement
plus two years, the immediate vesting of all stock options and awards granted to
him and the immediate payment of all incentive awards earned. The amount paid to
Mr. Gelman in fiscal 1995 is set forth in the compensation table, above. Mr.
Gelman's current annual salary is $350,000. As used in the agreement, "change in
control" means, without the consent of the Board of Directors, acquisition of
beneficial ownership of a majority of the outstanding voting shares of the
Company, a tender offer consummated for at least thirty-three percent (33%) of
the Company's Common Stock or acquisition of beneficial ownership of more than
fifty-one percent (51%) of the total fair market value of the Company's assets
by any person or entity (or more than one person or entity acting as a group),
or replacement of a majority of the members of the Company's Board of Directors
within a one year period by
11
<PAGE> 15
persons whose appointment or election is not endorsed by a majority of the Board
prior to the date of the appointment.
Kim A. Davis. Pursuant to an employment agreement, Kim A. Davis is employed
as President and Chief Operating Officer of the Company for a three-year term at
an annual minimum salary of $325,000 plus bonus, as determined by the Board of
Directors. The agreement provides for the use of an automobile by Mr. Davis at
no cost to him and for whole life insurance benefits in the amount of One
Million Dollars with premiums payable by the Company, and that Mr. Davis has the
right to participate in medical, disability, retirement and other benefit
programs on the same terms and conditions as other executive employees of the
Company. The active employment period under the agreement commenced August 1,
1995, and is automatically extended each year on August 1 for one additional
year unless notice of termination is given by the Company. Employment terminates
upon Mr. Davis' death or disability. Further, it may be terminated by the
Company with or without cause or by Mr. Davis. Should there have been no change
in control of the Company, upon termination by the Company without cause of Mr.
Davis' employment, Mr. Davis is to receive termination compensation equal to his
annual salary plus bonus in the year of termination, if the Company is then
achieving or exceeding its projected performance plan, or an amount equal to his
annual salary only, if the Company is not then achieving its projected
performance plan, payable annually for the greater of the remaining balance of
the agreement or two years. If there has been a change in control and Mr. Davis
resigns within one year of such a change or his employment is terminated by the
Company without cause, Mr. Davis is to receive termination compensation equal to
his annual salary plus bonus in the year of termination, if the Company is then
achieving or exceeding its projected performance plan, or an amount equal to his
annual salary only, if the Company is not then achieving its projected
performance plan, payable annually for the remaining balance of the agreement
plus two years, the immediate vesting of all stock options and awards granted to
him and the immediate payment of all incentive awards earned. The amount paid to
Mr. Davis in fiscal 1995 is set forth in the compensation table, above. Mr.
Davis' current annual salary is $325,000. As used in the agreement, "change in
control" means, without consent of the Board of Directors, acquisition of
beneficial ownership of a majority of the outstanding voting shares of the
Company, a tender offer consummated for at least thirty-three percent (33%) of
the Company's common stock or acquisition of beneficial ownership of more than
fifty-one percent (51%) of the total fair market value of the Company's assets
by any person or entity (or more than one person or entity acting as a group),
or replacement of a majority of the members of the Company's Board of Directors
within a one year period by persons whose appointment or election is not
endorsed by a majority of the Board prior to the date of the appointment.
James C. Marshall. Pursuant to an employment agreement, James C. Marshall
is employed as Senior Vice President of the Company for a two-year term at an
annual minimum salary of $142,000 plus an annual bonus award and other incentive
compensation, as determined by the Board of Directors. The active employment
period under the agreement is automatically extended each year on February 9th
for one additional year unless notice of termination is given. The agreement
also terminates upon Mr. Marshall's death or disability and may be terminated by
the Company or Mr. Marshall with or without cause upon 30 days written notice.
On termination of employment by the Company with or without cause, Mr. Marshall
is entitled to a payment of three times his then current annual salary plus all
amounts due under the remaining term of his employment agreement, as if the
agreement had not been terminated. At a current annual salary of $152,200, Mr.
Marshall would receive upon termination a payment of $456,600 plus any amount
due under the remainder of the term of his employment agreement. On termination
by Mr. Marshall of his employment with the Company or if his employment with the
Company is terminated solely because he has reached his 65th birthday, Mr.
Marshall is entitled to a payment of two times his annual salary; at his current
salary, Mr. Marshall would receive a payment of $304,400. If Mr. Marshall's
basic employment with the Company is terminated by reason of total disability,
he is entitled to receive his annual salary for the period then remaining under
his employment agreement with the Company, but he must perform supplemental
employment duties as assigned by the Chief Executive Officer of the Company. The
amount paid to Mr. Marshall in fiscal year 1995 pursuant to this agreement is
set forth in the compensation table above.
Robert L. Buker and Mark A. Sutter. Pursuant to Termination Benefit
Agreements, upon termination, Messrs. Buker and Sutter, Executive Officers of
the Company, each will be paid an amount equivalent to twelve months and six
months, respectively, of his annual salary. Based on current annual salary,
severance
12
<PAGE> 16
payments for Mr. Buker and Mr. Sutter would be $120,000 and $60,000,
respectively. Each agreement provides that the Company must pay the severance
payments when the Executive Officer is terminated unless he is terminated for
committing an illegal act. Each agreement further provides that, should
employment with the Company be terminated, either voluntarily or involuntarily,
within twenty-four (24) months after a change of control of the Company, the
Executive Officer will receive twice the amount under the normal severance
arrangement. In addition, in the event of termination, each will receive
reimbursement of his costs to obtain job placement services, not to exceed
$7,500, and medical and health insurance coverage for a period ending on the
earlier of the date which is twelve months from the date of his termination or
the date he commences new employment.
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
Securities and Exchange Commission rules stipulate that the Compensation
Committee of a public corporation must disclose specific reasoning in
determination of the compensation which was paid in the last fiscal year to each
of the Five Named Officers (and James J. Fahrner, who resigned from the Company
in June 1995) together with an explanation relating compensation paid to Company
performance. Philosophically, the Committee operates under the premises that
executive base salaries must be competitive within the Company's industry and
geographic region in order to attract and retain talented executives and that
incentive compensation should be directly and materially linked to operating
performance, both individual and corporate. The Company's Compensation Committee
is comprised of three outside directors, and, in recent years, John Geishecker
has served as Committee Chairman.
During Fiscal 1995, the Committee met three times to review various matters
relating to executive compensation, executive employee benefits and stock option
incentives. In June and August 1995, the Committee met at the request of the
Chief Executive Officer and the Chief Operating Officer to renegotiate new
long-term employment contracts for both these officers that would be in better
synchronization with their management chemistry for achieving positive operating
results.
In September 1995, the Committee again convened to review final senior
management contract negotiations and make its recommendations to the Board of
Directors. The Committee also reviewed individual officer performance with the
Chief Executive Officer and, where appropriate, adjusted the base salaries of
Company executives for the coming year based on the recommendations of both the
Chief Operating and Executive Officers. In the determination of base salaries,
the Committee reviewed industry and regional surveys of executive compensation
in comparable companies. Except for Mr. Davis, who assumed added
responsibilities during Fiscal 1995, the base salaries of the Five Named
Officers have remained unchanged from the prior fiscal year. Mr. Davis' 44%
increase in base compensation, in part, reflects a continuing realignment and
sharing of responsibilities between the office of the Chief Executive Officer
and the Chief Operating Officer. The Committee also reviewed the Chief Executive
Officer's recommendations for senior management incentive bonuses. The size of
the bonus pool is determined by the measure of realized corporate earnings as
related to budgeted expectations, as approved by the Board of Directors, while
individual participations in the pool are primarily determined by the
recommendations of the Chief Executive and Operating Officers, whose own
individual performance bonuses are predetermined by contract. Named Officers on
average received a 37% increment to their aggregate 1995 base compensation. In
all, fifteen members of senior management participated in the Fiscal 1995
$890,500 incentive bonus pool which grew 238% over the prior fiscal year.
Stock options, granted under the 1988 Stock Option Plan, are used by the
Company to attract and retain key executive officers and to recognize promotion
to additional responsibilities within the Company. These options provide
additional incentive to improve operational performance, as measured by the
Company's public market value. Further, under the proposed Executive Stock
Ownership Plan, as adopted by the Board of Directors on September 20, 1995,
executive officers will receive a portion of any annual incentive bonus in
Company stock until the executives own shares in an amount equal in value to at
least 50% of their base annual salaries.
13
<PAGE> 17
CHIEF EXECUTIVE OFFICER COMPENSATION
In determining Mr. Gelman's total compensation for Fiscal 1995, including
incentive compensation, the Committee and outside directors weighed not only the
factors outlined above but also his personal contributions to the Fiscal 1995
operating performance, which saw revenues increase 9% and net earnings increase
39%. This outstanding performance resulted from revenue enhancement, continuing
margin improvement and related cost containment programs, developed under the
Chief Executive Officer and implemented by the Chief Operating Officer. As a
result, outside directors, with the recommendation of the Compensation
Committee, approved a $300,000 incentive bonus and a 100,000 share stock option
to be divided equally between both officers. As with others of the Five Named
Officers who have not assumed additional responsibilities, Mr. Gelman's base
compensation has remained unchanged.
Robert M. Collins John A. Geishecker, Jr.
Nina I. McClelland Chairman
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Mr. Collins, Mr. Geishecker and Dr. McClelland served as the members of the
Compensation Committee in Fiscal 1995. No member of the Compensation Committee
has an interlocking or insider participation that would affect compensation
determination.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
During the last fiscal year, the Company paid $30,293 to KREW Team, Inc.
for financial consulting services, including related expenses, provided to the
Company. John A. Geishecker, Jr., a director of the Company, is President and a
director and shareholder of KREW Team, Inc.
14
<PAGE> 18
PERFORMANCE GRAPH
The following line graph compares the annual change in the cumulative total
shareholder return on the Company's Common Stock during the Company's last five
fiscal years with the annual change in the cumulative total return of the AMEX
Market Value Index and the AMEX High Technology Index. Shareholder returns shown
assume that $100 was invested in each of the Company's Common Stock, the AMEX
Market Value Index and the AMEX High Technology Index at July 31, 1990, and that
all dividends were reinvested.
COMPARISON OF FIVE YEAR CUMULATIVE TOTAL RETURN
AMONG GELMAN SCIENCES INC., THE AMEX MARKET VALUE INDEX
AND THE AMEX HIGH TECHNOLOGY INDEX
<TABLE>
<CAPTION>
MEASUREMENT PERIOD GELMAN AMEX MARKET AMEX HIGH
(FISCAL YEAR COVERED) SCIENCES INC VALUE TECH
<S> <C> <C> <C>
7/90 100 100 100
7/91 82 104 119
7/92 96 110 132
7/93 185 124 127
7/94 342 124 127
7/95 504 148 179
</TABLE>
15
<PAGE> 19
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
PRINCIPAL SHAREHOLDERS
The following table sets forth the beneficial ownership of the Company's
Common Stock of each person known to the Company to be the beneficial owner of
more than five percent (5%) of the total shares issued and outstanding on
November 6, 1995. Under rules and regulations promulgated by the Securities and
Exchange Commission, a person is deemed to be the "beneficial owner" of all the
shares with respect to which he has or shares voting power or investment power,
regardless of whether he is entitled to receive any economic benefit from his
interest in the shares. Except as otherwise indicated, ownership is direct. As
used herein, the term "voting power" means the power to vote or to direct the
voting of shares and "investment power" means the power to dispose of or to
direct the disposition of shares.
<TABLE>
<CAPTION>
NAME AND ADDRESS PERCENT
OF SHARES OF
BENEFICIAL OWNER BENEFICIALLY OWNED CLASS
--------------------------------------------------- ------------------ -------
<S> <C> <C>
Charles Gelman 973,821(a) 12.4%
600 South Wagner Road
Ann Arbor, MI 48103-9019
Prudential Investment Advisors 499,000 6.4%
5 Prudential Plaza
Newark, NJ 07102-3777
RCM Capital Management 668,400 8.5%
4 Embarcadero Center
San Francisco, CA 94111-4189
</TABLE>
- ---------------
(a) Mr. Gelman's beneficial ownership includes 7,426 shares allocated to him
under the Company's Employee Benefit Plans. The total does not include
284,781 shares held by the Employee Stock Ownership Plan with respect to
which he shares voting and investment power as a trustee.
16
<PAGE> 20
SECURITY OWNERSHIP OF MANAGEMENT
The following table provides certain information regarding the beneficial
ownership of the Company's Common Stock, as of November 6, 1995, by its
directors (including the nominees), the Five Named Officers, Mr. Fahrner, and
the directors and all executive officers of the Company as a group. Except as
otherwise indicated, ownership is direct.
<TABLE>
<CAPTION>
STOCK BENEFICIALLY OWNED
INCLUDING OPTIONS PERCENT
NAME AND WARRANTS(A) OF CLASS
----------------------- --------------------------- --------
<S> <C> <C>
Charles Gelman 973,821(b) 12.4%
Kim A. Davis 75,711 *
James C. Marshall 144,229 1.8%
Robert L. Buker 3,969 *
James J. Fahrner 8,303 *
Mark Sutter 14,577 *
Robert M. Collins 9,000 *
John A. Geishecker, Jr. 44,100 *
Saul H. Hymans 5,110 *
Hajime Kimura 9,000 *
Nina I. McClelland 8,750 *
Charles Newman 14,962 *
All directors and
executive officers as
a group (15 persons) 1,342,665 17.2%
</TABLE>
- ---------------
* Less than 1% of outstanding shares of the Company's Common Stock.
(a) The number of unexercised option and warrant shares which are exercisable
within 60 days after November 6, 1995, were: Charles Gelman, 0; Kim A.
Davis, 75,000; Robert L. Buker, 0; James J. Fahrner, 0; James C. Marshall,
86,399; Mark Sutter, 12,186; Robert M. Collins, 9,000; John A. Geishecker,
Jr., 44,100; Saul H. Hymans, 4,500; Hajime Kimura, 9,000; Nina I.
McClelland, 8,550; Charles Newman, 9,000; and all executive officers and
directors as a group (15 persons) 284,871. The warrants mentioned include
warrants issued to non-employee directors subject to shareholder approval
(see "PROPOSAL TO APPROVE WARRANTS ISSUED TO NON-EMPLOYEE DIRECTORS SINCE
SEPTEMBER 1, 1992," above).
(b) See note (a) to the table above setting forth the security ownership of
principal shareholders.
17
<PAGE> 21
AUDITORS
The accounting firm of Coopers & Lybrand has been selected as the Company's
independent certified public accountants for the fiscal year ended July 31,
1996. This firm has served as the Company's independent certified public
accountants since May 13, 1988. A representative of the auditors is expected to
be present at the Annual Meeting and will be available to answer questions. The
representative will have the opportunity to make a statement if he or she
desires to do so.
SHAREHOLDER PROPOSALS
Any proposals to be considered for inclusion in the proxy material to be
provided to shareholders of the Company for its next annual meeting to be held
in 1996 must be made by a qualified shareholder and must be received by the
Company no later than July 18, 1996.
GENERAL
The accompanying proxy is solicited by and on behalf of the Board of
Directors of the Company; its notice of meeting is attached to this Proxy
Statement. The entire cost of such solicitation will be borne by the Company. In
addition to the use of the mails, proxies may be solicited by personal
interview, telephone and telegram by directors, officers and employees of the
Company. Arrangements will be made with brokerage houses and other custodians,
nominees and fiduciaries for the forwarding of solicitation material to the
beneficial owners of stock held of record by such persons, and the Company will
reimburse them for reasonable out-of-pocket expenses incurred by them in
connection therewith.
The management and Board of Directors of the Company have no information
that other matters will be brought before the Annual Meeting. If, however, other
matters are properly presented, the accompanying proxy will be voted in
accordance with the best judgment of the proxy holders with respect to such
matters.
Edward J. Levitt
Secretary
Ann Arbor, Michigan
November 15, 1995
18
<PAGE> 22
GELMAN SCIENCES INC.
ANNUAL MEETING OF SHAREHOLDERS
DECEMBER 15, 1995
PROXY
The undersigned hereby appoints John A. Geishecker and Charles Newman,
or any one of them, with power of substitution in each, the proxies of
the undersigned at the Annual Meeting of Shareholders of Gelman
Sciences Inc. to be held December 15, 1995, and at any adjournment
thereof:
The Board of Directors recommends a vote FOR Proposals 1,2,3, and 4.
<TABLE>
<CAPTION>
Election of Directors, Nominees: (change of address)
<S> <C>
Kim A. Davis ---------------------------------------
Saul H. Hymans ---------------------------------------
Nina I. McClelland ---------------------------------------
---------------------------------------
(If you have written in the above space,
please mark the corresponding box on the
reverse side of this card.)
</TABLE>
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. THE SHARES
REPRESENTED BY THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE SPECIFICATIONS
MADE HEREIN. IF NO DIRECTION IS MADE, THE SHARES WILL BE VOTED FOR PROPOSALS
1,2,3, AND 4.
(CONTINUED AND TO BE DATED AND SIGNED ON REVERSE SIDE)
SHARES IN YOUR NAME
PLEASE MARK YOUR
/X/ VOTES AS IN THIS
EXAMPLE
<TABLE>
<S><C>
FOR WITHHELD FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN
1. Election of / / / / 2. Approval and / / / / / / 3. Approval and ratification / / / / / /
Directors ratification of of the Non-Employee
(see reverse) issuance of Director Stock Plan.
warrants to
non-employee 4. Approval and ratification / / / / / /
For, except vote withheld from directors since of the Executive Stock
the following nominee(s): September 1, 1992. Ownership Plan.
- ---------------------------------
Change
of / /
Address
Attend
Meeting / /
SIGNATURE(S) DATE PLEASE MARK, SIGN, DATE AND
------------------------------------------------ ----------------------- RETURN THIS PROXY CARD PROMPTLY
USING THE ENCLOSED ENVELOPE.
SIGNATURE(S) DATE
------------------------------------------------ -----------------------
NOTE: Please date this proxy and sign exactly as your name appears hereon. If the shares are
registered in more than one name, each joint owner should sign. When signing as attorney,
administrator, executor, personal representative, guardian or trustee, please add your
title to the signature. PLEASE SIGN AND RETURN THIS PROXY.
</TABLE>
<PAGE> 23
GELMAN SCIENCES INC.
ANNUAL MEETING OF SHAREHOLDERS
DECEMBER 15, 1995
The undersigned, as a participant in The Gelman Sciences 401(k) Savings Plan,
hereby directs the Trustee to vote (in person or by proxy) the number of shares
of Gelman Sciences Inc. Common Stock credited to the undersigned's account
under the plan at the Annual Meeting of Shareholders of Gelman Sciences Inc. to
be held December 15, 1995, and at any adjournment thereof.
The Board of Directors of Gelman Sciences Inc. recommends a vote
FOR Proposals 1,2,3, and 4.
<TABLE>
<CAPTION>
Election of Directors, Nominees: (change of address)
<S> <C>
Kim A. Davis ---------------------------------------
Saul H. Hymans ---------------------------------------
Nina I. McClelland ---------------------------------------
---------------------------------------
(If you have written in the above space,
please mark the corresponding box on the
reverse side of this card.)
</TABLE>
THIS DIRECTION CARD IS SOLICITED BY FIDELITY MANAGEMENT TRUST COMPANY ON BEHALF
OF THE BOARD OF DIRECTORS. THESE CONFIDENTIAL VOTING INSTRUCTIONS WILL BE SEEN
ONLY BY AUTHORIZED PERSONNEL OF THE TRUSTEE. THE SHARES REPRESENTED BY THIS
DIRECTION CARD WILL BE VOTED IN ACCORDANCE WITH THE SPECIFICATIONS MADE HEREIN.
IF NO DIRECTION IS MADE, THE SHARES WILL BE VOTED FOR PROPOSALS 1,2,3, AND 4.
(CONTINUED AND TO BE DATED AND SIGNED ON REVERSE SIDE)
SHARES IN YOUR NAME
PLEASE MARK YOUR
(X) VOTES AS IN THIS
EXAMPLE
<TABLE>
<S><C>
FOR WITHHELD FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN
1. Election of / / / / 2. Approval and / / / / / / 3. Approval and ratification / / / / / /
Directors ratification of of the Non-Employee
(see reverse) issuance of Director Stock Plan.
warrants to
non-employee 4. Approval and ratification / / / / / /
For, except vote withheld from Directors since of the Executive Stock
the following nominee(s): SEPTEMBER 1, 1992. Ownership Plan.
- ---------------------------------
Change
of / /
Address
Attend
Meeting / /
SIGNATURE(S): DATE PLEASE MARK, SIGN, DATE AND
------------------------------------------------ ----------------------- RETURN THIS DIRECTION
CARD PROMPTLY USING
THE ENCLOSED ENVELOPE
SIGNATURE(S): DATE
------------------------------------------------ -----------------------
NOTE: Please date this direction card and sign exactly as your name appears hereon. If the shares are
registered in more than one name, each joint owner should sign. When signing as attorney,
administrator, executor, personal representative, guardian or trustee, please add your
title to the signature. PLEASE SIGN AND RETURN THIS DIRECTION CARD.
</TABLE>
<PAGE> 24
APPENDIX
1
<PAGE> 25
AMENDMENT OF WARRANT AGREEMENT
TO: Charles Newman
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that each of the Warrant Agreements dated September 2, 1992, and July 17, 1994,
under which you were granted 9,000 shares (after adjustment for stock splits)
of the Common Stock, $0.10 par value, of the Corporation is hereby amended as
follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Charles Newman
- --------------------------
Charles Newman
Dated: June 5, 1995
2
<PAGE> 26
WARRANT AGREEMENT
TO: Charles Newman
FROM: Charles Gelman
DATE: September 2, 1992
Pursuant to and in accordance with a resolution of the Executive Committee
of the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted
at its meeting on September 2, 1992, the Corporation hereby grants you a
warrant (the "Warrant") to purchase 2,000 shares of the Common Stock, $.10 par
value, of the Corporation (the "Shares") at $7.50 per Share, upon the terms and
conditions contained in this Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise that portion
of the Warrant, if any, which is exercisable by you on the date of
termination of your service.
3
<PAGE> 27
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on the date of your death, may be exercised for a period of
180 days following your death, but in no event subsequent to the
expiration date of the Warrant, by your legal representative or by the
person or persons to whom your rights shall pass by will or by the
laws of descent and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding, you will
pay such amount to the Corporation to reimburse the Corporation for such
income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon the
exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution thereof and each
notice of exercise of the Warrant shall be accompanied by a representation
in writing signed by you
4
<PAGE> 28
to that effect. The Corporation may place a legend upon any certificate
representing the Shares purchased pursuant to exercise of the Warrant
noting that the transfer of such Shares may be restricted under the
Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or exchanged for a
different number or kind of shares of stock or other securities of the
Corporation or of another corporation, whether by reason of merger,
consolidation, recapitalization, reclassification, split-up, combination
of shares or otherwise, the number, price and kind of Shares subject to
the Warrant shall be appropriately adjusted.
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of the
Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Charles Newman
- ---------------------------------
Dated: September 2, 1992
-------------------------
5
<PAGE> 29
WARRANT AGREEMENT
TO: Charles Newman
FROM: Charles Gelman
DATE: June 17, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its meeting on June 17,
1994, the Corporation hereby grants you a warrant (the "Warrant") to purchase
3,000 shares of the Common Stock, $0.10 par value, of the Corporation (the
"Shares") at $16.38 per Share, upon the terms and conditions contained in this
Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the Warrant is
exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated earlier
upon your termination of service as a member of the Board of Directors of
the Corporation or your death, which are governed by Paragraphs 5 and 6 of
this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the right for a
period of 90 days following such termination, but in no event subsequent
to the expiration date of the Warrant, to exercise that portion of the
Warrant, if any, which is exercisable by you on the date of termination of
your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it is
exercisable on the date of your death, may be exercised for a period of
180 days following your
6
<PAGE> 30
death, but in no event subsequent to the expiration date of the Warrant, by
your legal representative or by the person or persons to whom your rights
shall pass by will or by the laws of descent and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of Shares to be
purchased, the name in which you desire to have the shares registered,
your address and your social security number and shall be accompanied by
payment in full in cash of the aggregate exercise price for the number of
Shares purchased and by the representation required by Paragraph 10 of
this Agreement if the Shares to be issued upon exercise of the Warrant
have not been registered under the Securities Act of 1933, as amended (the
"Securities Act"). Such exercise shall be effective only upon the actual
receipt of such written notice and no rights or privileges of a
shareholder of the Corporation in respect of any of the Shares issuable
upon exercise of any part of the Warrant shall inure to you or any other
person who is entitled to exercise the Warrant unless and until
certificates representing such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
7
<PAGE> 31
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Charles Newman
- ------------------------
Charles Newman
Dated: June 17, 1994
-----------------
8
<PAGE> 32
AMENDMENT OF WARRANT AGREEMENT
TO: Robert M. Collins
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that the Warrant Agreement dated July 17, 1994, under which you were granted
9,000 shares (after adjustment for stock splits) of the Common Stock, $0.10 par
value, of the Corporation is hereby amended as follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Robert M. Collins
- ----------------------------
Robert M. Collins
Dated: June 5, 1995
9
<PAGE> 33
WARRANT AGREEMENT
TO: Robert M. Collins
FROM: Charles Gelman
DATE: June 17, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its meeting on June 17,
1994, the Corporation hereby grants you a warrant (the "Warrant") to purchase
6,000 shares of the Common Stock, $0.10 par value, of the Corporation (the
"Shares") at $16.38 per Share, upon the terms and conditions contained in this
Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise
that portion of the Warrant, if any, which is exercisable by you on the
date of termination of your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on
10
<PAGE> 34
the date of your death, may be exercised for a period of 180 days following
your death, but in no event subsequent to the expiration date
of the Warrant, by your legal representative or by the person or persons to
whom your rights shall pass by will or by the laws of descent
and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
11
<PAGE> 35
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Robert M. Collins
- ----------------------------
Robert M. Collins
Dated: June 17, 1994
--------------------
12
<PAGE> 36
AMENDMENT OF WARRANT AGREEMENT
TO: John A. Geishecker, Jr.
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that the Warrant Agreement dated July 17, 1994, under which you were granted
4,500 shares (after adjustment for stock splits) of the Common Stock, $0.10 par
value, of the Corporation is hereby amended as follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ John A. Geishecker, Jr.
- ---------------------------------
John A. Geishecker, Jr.
Dated: June 5, 1995
13
<PAGE> 37
WARRANT AGREEMENT
TO: John A. Geishecker, Jr.
FROM: Charles Gelman
DATE: June 17, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its meeting on June 17,
1994, the Corporation hereby grants you a warrant (the "Warrant") to purchase
3,000 shares of the Common Stock, $0.10 par value, of the Corporation (the
"Shares") at $16.38 per Share, upon the terms and conditions contained in this
Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise
that portion of the Warrant, if any, which is exercisable by you on the
date of termination of your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on
14
<PAGE> 38
the date of your death, may be exercised for a period of 180 days following
your death, but in no event subsequent to the expiration date
of the Warrant, by your legal representative or by the person or persons to
whom your rights shall pass by will or by the laws of descent
and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
15
<PAGE> 39
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ John A. Geishecker, Jr.
- --------------------------------
John A. Geishecker, Jr.
Dated: June 17, 1994
------------------------
16
<PAGE> 40
AMENDMENT OF WARRANT AGREEMENT
TO: Dr. Saul H. Hymans
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that the Warrant Agreement dated July 17, 1994, under which you were granted
4,500 shares (after adjustment for stock splits) of the Common Stock, $0.10 par
value, of the Corporation is hereby amended as follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Saul H. Hymans
- -----------------------------
Dr. Saul H. Hymans
Dated: June 5, 1995
17
<PAGE> 41
WARRANT AGREEMENT
TO: Dr. Saul H. Hymans
FROM: Charles Gelman
DATE: June 17, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its meeting on June 17,
1994, the Corporation hereby grants you a warrant (the "Warrant") to purchase
3,000 shares of the Common Stock, $0.10 par value, of the Corporation (the
"Shares") at $16.38 per Share, upon the terms and conditions contained in this
Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise
that portion of the Warrant, if any, which is exercisable by you on the
date of termination of your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on
18
<PAGE> 42
the date of your death, may be exercised for a period of 180 days following
your death, but in no event subsequent to the expiration date
of the Warrant, by your legal representative or by the person or persons to
whom your rights shall pass by will or by the laws of descent
and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
19
<PAGE> 43
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Saul H. Hymans
- ------------------------
Dr. Saul H. Hymans
Dated: June 17, 1994
------------------
20
<PAGE> 44
AMENDMENT OF WARRANT AGREEMENT
TO: Dr. Nina McClelland
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that the Warrant Agreement dated July 17, 1994, under which you were granted
4,500 shares (after adjustment for stock splits) of the Common Stock, $0.10 par
value, of the Corporation is hereby amended as follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Nina McClelland
- --------------------------
Dr. Nina McClelland
Dated: June 5, 1995
21
<PAGE> 45
WARRANT AGREEMENT
TO: Dr. Nina McClelland
FROM: Charles Gelman
DATE: June 17, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its
meeting on June 17, 1994, the Corporation hereby grants you a warrant (the
"Warrant") to purchase 3,000 shares of the Common Stock, $0.10 par
value, of the Corporation (the "Shares") at $16.38 per Share, upon the terms
and conditions contained in this Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise
that portion of the Warrant, if any, which is exercisable by you on the
date of termination of your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on
22
<PAGE> 46
the date of your death, may be exercised for a period of 180 days following
your death, but in no event subsequent to the expiration date
of the Warrant, by your legal representative or by the person or persons to
whom your rights shall pass by will or by the laws of descent
and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
23
<PAGE> 47
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Nina McClelland
- ---------------------------
Dr. Nina McClelland
Dated: June 17, 1994
-------------------
24
<PAGE> 48
AMENDMENT OF WARRANT AGREEMENT
TO: Dr. Hajime Kimura, M.D., Ph.D.
FROM: Charles Gelman
DATE: June 5, 1995
Pursuant to, in accordance with and in implementation of a resolution of
the Board of Directors of Gelman Sciences Inc. (the "Corporation") adopted at
its meeting on March 18, 1995, and so as to bring the grant of certain warrants
into compliance with federal securities laws, you and the Corporation agree
that the Warrant Agreement dated September 2, 1994, under which you were
granted 9,000 shares of the Common Stock, $0.10 par value, of the Corporation
is hereby amended as follows:
1. The warrant may not be exercised in whole or in part within six months
from the date of grant.
2. The grant of the warrant is subject to the approval and ratification
of the shareholders of the Corporation and shall be put before the
shareholders at the next annual meeting of shareholders following this
amendment.
Upon signing, this amendment shall be deemed to have been a part of the
original agreement effective as of the date thereof.
GELMAN SCIENCES INC.
By: /s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Hajime Kimura
- ---------------------------------
Dr. Hajime Kimura, M.D., Ph.D.
Dated: June 5, 1995
25
<PAGE> 49
WARRANT AGREEMENT
TO: Dr. Hajime Kimura, M.D., Ph.D.
FROM: Charles Gelman
DATE: September 2, 1994
Pursuant to and in accordance with a resolution of the Board of Directors
of Gelman Sciences Inc. (the "Corporation") adopted at its meeting on September
2, 1994, the Corporation hereby grants you a warrant (the "Warrant") to
purchase 9,000 shares of the Common Stock, $0.10 par value, of the Corporation
(the "Shares") at $14.25 per Share, upon the terms and conditions contained in
this Agreement.
1. The Warrant is not intended to be an incentive stock option within the
meaning of the Internal Revenue Code of 1986, as amended.
2. The Warrant may not be transferred by you otherwise than by will or by the
laws of descent and distribution and, during your lifetime, the
Warrant is exercisable only by you.
3. Subject to the terms contained in this Agreement, you may exercise the
Warrant in whole or in part beginning on the date of this Agreement.
4. This Warrant will expire (to the extent not previously exercised) on the
tenth anniversary of the date of this Agreement, unless terminated
earlier upon your termination of service as a member of the Board of
Directors of the Corporation or your death, which are governed by
Paragraphs 5 and 6 of this Agreement, respectively.
5. If your service as a member of the Board of Directors of the Corporation
terminates for any reason other than your death, you have the
right for a period of 90 days following such termination, but in no event
subsequent to the expiration date of the Warrant, to exercise
that portion of the Warrant, if any, which is exercisable by you on the
date of termination of your service.
6. If your service as a member of the Board of Directors of the Corporation
terminates by reason of your death, the Warrant, to the extent it
is exercisable on
26
<PAGE> 50
the date of your death, may be exercised for a period of 180 days following
your death, but in no event subsequent to the expiration date
of the Warrant, by your legal representative or by the person or persons to
whom your rights shall pass by will or by the laws of descent
and distribution.
7. The Warrant shall be exercised by giving a written notice to the Secretary
of the Corporation. Such notice shall specify the number of
Shares to be purchased, the name in which you desire to have the shares
registered, your address and your social security number and shall
be accompanied by payment in full in cash of the aggregate exercise price
for the number of Shares purchased and by the representation
required by Paragraph 10 of this Agreement if the Shares to be issued upon
exercise of the Warrant have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"). Such exercise
shall be effective only upon the actual receipt of such written
notice and no rights or privileges of a shareholder of the Corporation in
respect of any of the Shares issuable upon exercise of any part
of the Warrant shall inure to you or any other person who is entitled to
exercise the Warrant unless and until certificates representing
such Shares shall have been issued.
8. Nothing contained in this Agreement, nor any action taken by the
Corporation, shall confer upon you any right with respect to continuation
of your service as a member of the Board of Directors of the Corporation.
9. If, upon or as a result of your exercise of the Warrant, there shall be
payable by the Corporation any amount for income tax withholding,
you will pay such amount to the Corporation to reimburse the Corporation
for such income tax withholding.
10. Unless a registration statement covering the Shares subject to the Warrant
is in effect under the Securities Act, all Shares purchased upon
the exercise of the Warrant shall be acquired for investment and not with a
view to, or for, sale in connection with any distribution
thereof and each notice of exercise of the Warrant shall be accompanied by
a representation in writing signed by you to that effect. The
Corporation may place a legend upon any certificate representing the Shares
purchased pursuant to exercise of the Warrant noting that the
transfer of such Shares may be restricted under the Securities Act.
11. In the event that the outstanding shares of Common Stock of the Corporation
shall be increased by a stock dividend or changed into or
exchanged for a different number or kind of shares of stock or other
securities of the Corporation or of another corporation, whether by
reason of merger, consolidation, recapitalization, reclassification,
split-up, combination of shares or otherwise, the number, price and
kind of Shares subject to the Warrant shall be appropriately adjusted.
27
<PAGE> 51
12. The Shares issued upon exercise of the Warrant may consist in whole or in
part of the authorized and unissued or reacquired Common Stock of
the Corporation.
Sincerely yours,
/s/ Charles Gelman
-----------------------------
Charles Gelman
Chairman of the Board and CEO
The above is agreed to and accepted:
/s/ Hajime Kimura
- -----------------------------------
Dr. Hajime Kimura, M.D., Ph.D.
Dated: September 2, 1994
----------------------------
28
<PAGE> 52
GELMAN SCIENCES INC.
NON-EMPLOYEE DIRECTOR STOCK PLAN
NAME AND GENERAL PURPOSE OF PLAN. The name of the plan is the Gelman Sciences
Inc. Non-Employee Director Stock Plan (the "Plan"). The Plan was adopted by
the Board of Directors (the "Board") of Gelman Sciences Inc. (the "Company") on
September 20, 1995, subject to shareholder approval and ratification. The
purpose of the Plan is to provide non-employee directors of the Company an
opportunity to participate in future appreciation in the share value of the
Company's stock, further aligning the interests of non-employee directors with
the interests of shareholders of the Company, with the goal of maximizing
return on shareholder investment. The opportunity to participate in Company
stock appreciation is intended to enable the Company to attract and retain
superior Board members. The Plan consists of two components: (1) stock
options and (2) receipt of all or part of a non-employee director's fees in
Company stock, in lieu of cash compensation, at the election of the
non-employee director.
1. OPTIONS ISSUABLE UNDER PLAN. During each fiscal year, the
Non-Employee Director Stock Plan Committee (the "Committee") will
issue options, in accordance with Section 2, below, to purchase shares
of the common stock of the Company ("Shares"). The maximum number of
Shares with respect to which options may be granted under the Plan in
any fiscal year of the Company is 41,000, subject to adjustment
pursuant to Section 4, below (the "Plan Limit"). The Shares issued
upon exercise of an option may be authorized but unissued shares or
shares which have been reacquired by the Company, or a combination
thereof.
2. OPTION PARTICIPANTS AND GRANTS. Upon initial election to office, each
Participant will be granted an option to purchase 9,000 Shares
and, on July 31 of each year following reelection to office, an option
to purchase 1,000 Shares. Each such option will become first
exercisable six months after the date of the grant, provided that the
option recipient's status as a non-employee director of the
Company has not changed and the Plan then remains in effect.
Successive options may be granted to the same person, whether or not
any option previously granted to such person remains unexercised. Each
option granted pursuant to the Plan is referred to hereinafter as
an "Option," and each non-employee director of the Company is referred
to hereinafter as a "Participant."
3. OPTION PRICE. The exercise price per share underlying each Option
will be the closing price per share of Common Stock on the American
Stock Exchange on the last trading day immediately preceding the date
of grant. The Option exercise price will be payable in whole or
in part, at the election of the Participant, (i) in cash or (ii) in
shares of Common Stock valued at the closing price for Common Stock
on the American Stock Exchange on the last trading
29
<PAGE> 53
day immediately preceding the date of exercise, to the extent
permitted by all applicable laws and regulations, unless the
Committee determines that the application of any Financial Accounting
Standard Board rule affecting the tender of shares would be
detrimental to the best interests of the Company.
4. ADJUSTMENTS. The Committee will provide for such adjustments in the
exercise price per share with respect to each outstanding Option
and in the number of shares covered by each outstanding Option as is
equitably required to prevent dilution or enlargement of the
rights of any Participant that would otherwise result from (a) any
stock dividend, stock split, combination of shares, recapitalization
or other change in the capital structure of the Company, (b) any
merger, consolidation, separation, reorganization or partial or
complete liquidation or (c) any transaction or event having an effect
similar to any of the foregoing.
5. EXPIRATION; TRANSFER; EXERCISE; RELOAD OPTIONS. Each Option granted
under the Plan will expire on the date that is ten (10) years
from the date of grant. No Option will be transferable by a
Participant otherwise than by will or the laws of descent and
distribution. A Participant may exercise an Option UPON RECEIPT BY
the Company of such forms as the Company may require in advance of
exercise and the required payment. A stock certificate may be issued
as soon as practical after exercise and payment. An Option is
exercisable during the Participant's lifetime only by the Participant,
except that in case of incompetence or disability of a
Participant, an Option may be exercised on behalf of the Participant
by his or her guardian or legal representative. The Company will
assist any Participant in effecting a "cashless exercise" of any
Option; that is, if, immediately following an Option exercise, the
Participant decides to sell all or any of the shares underlying the
Option, the Participant will receive (in lieu of a certificate
evidencing such shares) the amount by which the sale price of such
shares exceeds the exercise price, after deducting applicable taxes
and brokerage fees, but without deduction for interest that might
otherwise be paid on any advance of monies to the Participant between
the exercise and settlement dates. Each Participant will receive an
automatic grant of an additional Option (a "reload option") for an
equal amount of shares at an option price determined in accordance
with Section 3 above upon the exercise of an Option through the
delivery of shares of Common Stock, in the manner set forth in the
Stock Option Agreement (defined in Section 6, below). The number of
Shares with respect to which reload options are granted will be
counted against the Plan Limit as of the date of grant.
6. STOCK OPTION AGREEMENT; CANCELLATION. The granting of any Option
shall be evidenced by a stock option agreement ("Stock Option
Agreement") which may contain such other terms, provisions and
conditions not inconsistent with the terms of the Plan as determined by
the Committee. Such Stock Option Agreement may, with the concurrence
of the affected Participant (and subject to the limitations set
forth in Section 10, below), be amended by the Committee, provided
that the terms of each such amendment are not inconsistent with the
terms of the Plan. The Committee may, with the concurrence of the
affected
30
<PAGE> 54
Participant, cancel any Option granted under the Plan or any warrant
for the purchase of the Company's common stock granted to any non-
employee director of the Company pursuant to one or more warrant
agreements entered into prior to September 20, 1995. In the event of
any cancellation of an outstanding Option, the Company may authorize
the granting of one or more new Options under the Plan in such
manner, at such price and subject to similar terms and conditions as
would have been applicable had the cancelled Option not been
granted. In the event of any cancellation of an outstanding warrant,
the Committee may authorize the granting of one or more Options
under the Plan for the same number of shares at the same exercise
price and upon the terms set forth in the warrant, or, at the
election of the Participant, providing for exercise in such manner, at
such price and subject to similar terms and conditions as would
have been applicable had the cancelled warrant not been granted.
7. STOCK IN LIEU OF DIRECTORS' FEES. Each Participant may elect to
receive shares of Common Stock in an amount equal to, and in lieu of,
all or part of the fees that otherwise would be paid by the Company to
such Participant as compensation for serving on the Board. For
purposes of such payment in stock, a share of Common Stock will be
valued at the closing price on the American Stock Exchange on the
last trading day of the fiscal quarter prior to the scheduled date for
payment of such fees. The value of any fractional share amount
will be paid in cash. Such election may be made by written notice to
the Company's Secretary prior to the start of each fiscal year.
8. TERMINATION OF PARTICIPATION. In the event of the death of any
Participant, any Option issued to that Participant which is
exercisable on the date of death may be exercised for a period of 180
days following the date of death, but in no event subsequent to the
expiration date of that Option, by the legal representative of the
estate of the Participant or by the person or persons to whom the
Participant's rights shall pass by will or by the laws of descent and
distribution. In the event a Participant's service on the Board
is terminated for any other reason, to the extent any Option issued to
that Participant is exercisable on the date of termination, that
Option may be exercised by the Participant for a period of 90 days
following the date of termination, but in no event subsequent to the
expiration date of that Option.
9. ADMINISTRATION. The Plan will be administered by the Committee,
comprised initially of three or more directors or executive officers of
the Company, none of whom may be a Participant, but each of whom may
be an employee or employee-director of the Company. A majority of
Committee members will constitute a quorum, and the action of a
majority of the members of the Committee present at any meeting at
which a quorum is present, or the unanimous written action of the
Committee, will be considered the action of the Committee.
10. PLAN AMENDMENT; TERMINATION. This Plan is subject to initial
ratification and approval of the Company's shareholders, but may be
terminated or amended
31
<PAGE> 55
thereafter from time to time by the Committee. However, no such
amendment by the Committee shall (a) increase the maximum number of
shares of Common Stock that may be issued under this Plan, subject to
adjustments pursuant to Section 4 above, (b) change the
designation in Section 2 of the persons eligible to be granted Option
or (c) cause Rule 16b-3 (or any successor rule) promulgated by
the Securities and Exchange Commission (the "Commission") under the
Securities Exchange Act of 1934 to cease to be applicable to this
Plan without further approval of the shareholders of the Company.
Neither the Plan, nor any Stock Option Agreement, may be amended
more than once every six months, other than to comport with changes in
the Internal Revenue Code, the Employee Retirement Security Act,
or the rules thereunder, or rules promulgated by the Commission.
11. GOVERNING RULES. This Plan is intended to comply with and be subject
to Rule 16b-3 as in effect prior to May 1, 1991. The Committee
may at any time elect that this Plan shall be subject to a successor
to this rule and, without shareholder approval, make any and all
amendments to this Plan that are necessary to comply with the
provisions of the Rule as then in effect or make any other amendments
that do not require shareholder approval under applicable rules and
regulations then in effect.
32
<PAGE> 56
GELMAN SCIENCES INC.
EXECUTIVE STOCK OWNERSHIP PLAN
1. PURPOSE
The Gelman Sciences Inc. Executive Stock Ownership Plan (the "Plan")
is intended to foster and promote the long-term growth and
performance of Gelman Sciences Inc. (the "Company") by requiring and
enabling the acquisition of a significant personal equity interest
in the Company by those Company executives upon whose judgment and
efforts the Company is largely dependent for the successful conduct
of its business. As equity holders, Company executives will
participate in future appreciation in the share value of the Company's
stock, thus further aligning their interests with the interests of
other shareholders of the Company, with the goal of maximizing
return on shareholder investment. The opportunity to participate in
Company stock appreciation should enable the Company to attract
and retain key executives critical to the long-term success of the
Company. The Plan was adopted by the Company's Board of Directors
on September 20, 1995, with an effective date of August 1, 1995,
subject to shareholder approval and ratification.
2. BACKGROUND
The Plan is a feature of the Company's Executive Compensation Plan,
also adopted by the Board on September 20, 1995, with an effective
date of August 1, 1995. Pursuant to the Executive Compensation Plan,
the Board or its Compensation Committee (the "Committee") will
make an annual determination as to the dollar amount of a bonus pool
to be allocated among the Company's executive officers and other
employees. It is the goal of the Company that each executive officer
acquire and retain ownership of no fewer than that number of
shares of the Company's common stock ("Common Stock") with a value
equal to fifty percent (50%) of such officer's annual base salary
(the "Equity Value Requirement"), as adjusted from time to time.
Consistent with that goal, the annual bonus paid to each executive
officer will be paid in the form of a specified amount of Common
Stock, and the remainder of the bonus will be paid in cash. As of
each July 31st during the period in which the Plan is in effect, the
value of each executive officer's beneficial ownership of Common
Stock will be calculated, using the closing price on the principal
stock exchange on which the Common Stock is then traded for such
day, or, if it is not a trading day, then on the last trading day
immediately preceding such day. If the Equity Value Requirement is
not met by an executive officer as of any July 31st, the annual bonus
received by that officer for that year will have a stock
component. The size of the stock component will be sufficient to
satisfy the Equity Value Requirement, subject to the limitation that
the value of the stock component paid to an executive officer with
respect to any year will not exceed the lesser of thirty percent
(30%) of that officer's annual bonus or ten percent (10%) of such
officer's annual base salary for that year.
3. ADMINISTRATION
33
<PAGE> 57
The Plan will be administered by a committee ("Committee"), comprised
of three or more disinterested members of the Board, none of whom
will be an employee of the Company or a participant in the Plan. A
majority of Committee members will constitute a quorum, and the
action of a majority of the members of the Committee present at any
meeting at which a quorum is present, or the unanimous written
action of the Committee, will be considered the action of the
Committee. Except for the terms and conditions explicitly set forth in
the Plan, the Committee will have the authority, in its discretion, to
determine all matters relating to awards under the Plan. All
decisions made by the Committee pursuant to the provisions of the Plan
and related orders or resolutions of the Board shall be final
and conclusive.
4. PARTICIPANTS
The Chief Executive Officer, the Chief Operating Officer and all other
executive officers of the Company will participate in the Plan.
5. STOCK SUBJECT TO THE PLAN; ADJUSTMENTS
The stock awarded under the Plan will be shares of Common Stock and
may be authorized and unissued shares or shares now held or
subsequently acquired by the Company or a combination thereof, as the
Board may from time to time determine. The aggregate number of
shares to be awarded under the Plan will not exceed 100,000, subject
to adjustment for any increase or decrease in the number of issued
shares of Common Stock resulting from any reorganization,
capitalization, stock split, stock dividend or similar corporate
transaction.
6. STOCK AWARDS
Stock awards under the Plan will be determined pursuant to the
provisions of Section 2, above.
7. WITHHOLDING TAXES
The Company will have the right to deduct from any award made under
the Plan an amount sufficient to cover withholding required by law
for any federal, state or local taxes or to take such other action as
may be necessary to satisfy any such withholding obligations,
including the withholding from any other cash amounts due or to become
due from the Company to the participant an amount equal to such
taxes.
8. TERM OF THE PLAN
The Plan is effective as of August 1, 1995, and shall remain in full
force and effect until all the Common Stock subject to it shall
have been issued pursuant to the provisions hereof, unless sooner
terminated by the Board.
9. PLAN AMENDMENT; TERMINATION
34
<PAGE> 58
This Plan is subject to initial ratification and approval by the
Company's shareholders, but may be terminated or suspended or amended
thereafter from time to time by the Committee or the Board; provided,
however, no amendment by the Committee or the Board shall (a)
increase the maximum number of shares of Common Stock that may be
issued under the Plan, subject to adjustments pursuant to Section 5
above, (b) change the designation in Section 4 of the Plan
participants or (c) cause Rule 16b-3 (or any successor rule)
promulgated by the Securities and Exchange Commission (the
"Commission") under the Securities Exchange Act of 1934 (the
"Exchange Act") to cease to be applicable to this Plan, without
further approval of the shareholders of the Company. The Plan may not
be amended more than once every six months, other than to comport with
changes in the Internal Revenue Code, the Employee Retirement Income
Security Act, or the rules thereunder, or rules promulgated by the
Commission.
10. INDEMNIFICATION
Each person who is or shall have been a member of the Committee shall
be indemnified and held harmless by the Company against and from
any loss, cost, liability, or expense that may be imposed upon or
reasonably incurred by him or her in connection with or resulting
from any claim, action, suit, or proceeding to which he or she may be
a party or in which he or she may be involved by reason of any
action taken or failure to act under the Plan and against and from any
and all amounts paid by him or her in settlement thereof, with
the Company's approval, or paid by him or her in satisfaction of any
judgment in any such action, suit, or proceeding against him or
her, provided he or she shall give the Company an opportunity, at its
own expense, to handle and defend the same before he or she
undertakes to handle and defend it on his own behalf. The foregoing
right of indemnification shall not be exclusive of any other
rights of indemnification to which any such person may be entitled
under the Company's Articles of Incorporation or By-laws, as a
matter of law, or otherwise, or any power that the Company may have to
indemnify or hold such person harmless.
35
<PAGE> 59
11. REQUIREMENTS OF LAW
The issuance of Common Stock under the Plan will be subject to all
applicable laws, rules, and regulations, and to such approvals by
any governmental agencies or national securities exchanges as may be
required. The Plan, and all agreements hereunder, shall be
construed in accordance with and be governed by the laws of the State
of Michigan.
It is the intention of the Company that the Plan will comply in all
respects with Rule 16b-3, including any successor provision to Rule
16b-3, and, if any Plan provision is later found not to be in
compliance with Section 16 of the Exchange Act, that provision will be
deemed null and void, and in all events the Plan will be construed in
favor of its meeting the requirements of Rule 16b-3.
Specifically, the Plan is intended to comply with and be subject to
Rule 16b-3 as in effect prior to May 1, 1991. The Committee may at
any time elect that this Plan shall be subject to a successor to this
rule and, without shareholder approval, make any and all
amendments to this Plan that are necessary to comply with the
provisions of the Rule as then in effect or make any other amendments
that do not require shareholder approval under applicable rules and
regulations then in effect. Notwithstanding anything in the Plan
to the contrary, the Board, in its absolute discretion, may bifurcate
the Plan so as to restrict, limit or condition the use of any
provision of the Plan to participants who are subject to Section 16 of
the Exchange Act without so restricting, limiting or
conditioning the Plan with respect to other participants, if any.
36
